CASP3 and B-cell chronic lymphocytic leukemia: Treatment of JVM3 cells with 5 and 10 μM dasatinib, an inducer of apoptosis in CLL [29], caused cleavage of both caspase 3 and PARP (Figure 2B), thus confirming that there was no defect in the caspase 3/7 apoptotic pathway in this cell line.